Considering that USP30 is upregulated in the skin tissues of patients with diabetic foot ulcers, targeting USP30 with the inhibitor MF-094 seems to be promising for promoting wound healing in diabetic rats and suppressing NLRP3 inflammasome activation [184]. Here, USP30 is linked to diabetic foot.